16 results
8-K
EX-99.2
RLAY
Relay Therapeutics Inc
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
rates Diversity & inclusion advisory group Training and development opportunities Equitable compensation 4 clinical programs Committed to clinical … consumption Hazardous and lab waste management Non-hazardous waste management Average Tenure 5yrs Racial/Ethnic Diversity 38% Women 38% Independence
8-K
EX-99.2
RLAY
Relay Therapeutics Inc
18 Apr 23
Regulation FD Disclosure
10:42am
diversity of solid tumors, predominantly tumor types not predicted to be sensitive to single agent PI3Kα inhibition. The RLY-2608 + fulvestrant combination
PRE 14A
eui571
1 Apr 22
Preliminary proxy
4:30pm
DEF 14A
8ry400n zb
7 Apr 21
Definitive proxy
4:16pm
10-K
xkzw6d2 ryl8b92i3fr
25 Mar 21
Annual report
4:31pm
424B4
f065y0 rg
16 Jul 20
Prospectus supplement with pricing info
4:34pm
S-1/A
vx6ffxd8bqx
9 Jul 20
IPO registration (amended)
7:17am
S-1
f4il4h6niv1j8
24 Jun 20
IPO registration
5:03pm
DRS
vnih2mdozq z0
22 May 20
Draft registration statement
12:00am
- Prev
- 1
- Next